Mirum Pharmaceuticals, Inc. MIRM

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

We are a biopharmaceutical company dedicated to transforming the treatment of rare diseases.

We have three approved medicines: LIVMARLI® (maralixibat) ("Livmarli"), CHOLBAM® (cholic acid) capsules ("Cholbam"), and CTEXLI® (chenodiol) tablets ("Ctexli").

Livmarli is a novel, orally administered, minimally-absorbed ileal bile acid transporter ("IBAT") inhibitor ("IBATi") that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome ("ALGS") in the United States ("U.S."), the European Union ("EU") and various other countries around the world and for cholestatic pruritus in patients with progressive familial intrahepatic cholestasis ("PFIC") in the U.S., Canada and Japan and for the treatment of PFIC in the EU. We market and commercialize Livmarli in the U.S., Canada and certain countries in Europe through our specialized and focused commercial team. We have also entered into license and distribution agreements with several rare disease companies for the commercialization of Livmarli in additional countries. We are also seeking to add to the approved indications for Livmarli by conducting the EXPAND study in settings of cholestatic pruritus due to other rare conditions.

Last close 80.39 2026-10-23
Market cap $5.22B 2026-06-30 share count
52-week range 63.23 - 130.00

Valuation FY2025 figures against the last close

P/S10.0x
P/E—
P/FCF95.1x
EV/EBITDA2,476.2x
Dividend yield—
Diluted EPS-0.47

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue $521.3M$336.9M$186.4M$77.1M$19.1M$0———
SG&A $257.0M$202.2M$145.9M$89.1M$59.2M$22.7M$11.8M——
Total operating expenses $543.4M$424.5M$295.5M$208.3M$192.6M$104.3M$54.7M——
Operating income -$22.1M-$87.6M-$109.2M-$131.2M-$173.4M-$104.3M-$54.7M——
Interest expense $14.4M$14.3M$15.1M$16.0M—————
Pre-tax income -$21.4M-$86.9M-$162.4M-$142.1M-$84.0M-$103.3M-$52.5M——
Income tax $1.9M$1.0M$991.0K$6.4M$37.0K$6.0K$21.0K——
Net income -$23.4M-$87.9M-$163.4M-$135.7M-$84.0M-$103.3M-$52.6M——
EPS, basic -0.47-1.85-4.00-4.01-2.77————
EPS, diluted -0.47-1.85-4.00-4.02-2.77-4.09-4.58——
Shares, diluted (wtd. avg.) 50.2M47.5M40.9M34.0M30.3M————

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents $296.7M$222.5M$286.3M$28.0M$31.3M$142.1M$12.0M$52.0M—
Short-term investments $86.6M$57.8M$0$123.7M$125.2M$89.7M$104.7M——
Receivables $123.3M$78.3M$68.0M$24.0M$3.3M$0———
Inventory $24.9M$22.4M$22.3M$5.6M$1.5M$0———
Total current assets $549.7M$392.8M$387.5M$190.2M$166.6M$236.3M$119.4M$52.0M—
Property, plant and equipment $1.9M$1.1M$706.0K$914.0K$981.0K$1.3M$1.4M$0—
Other intangibles $260.9M$249.8M$252.9M$59.0M$18.7M————
Total assets $842.8M$670.8M$646.6M$352.9M$294.7M$240.9M$146.7M$52.0M—
Accounts payable $9.6M$14.6M$7.4M$8.7M$9.2M$3.2M$3.4M$269.0K—
Total current liabilities $205.8M$126.6M$87.1M$64.7M$42.6M$18.5M$13.1M$2.4M—
Total liabilities $528.1M$445.1M$398.0M$210.9M$174.4M$68.8M$16.4M$2.4M—
Retained earnings -$667.5M-$644.2M-$556.2M-$392.8M-$257.2M-$173.2M-$69.9M-$17.3M—
Total equity $314.7M$225.6M$248.7M$142.0M$120.2M$172.1M$130.3M-$17.3M$0

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating cash flow $55.8M$10.3M-$70.9M-$120.1M-$132.8M-$89.1M-$39.4M——
Depreciation and amortisation $24.2M$23.6M$10.8M$3.2M$595.0K$305.0K$139.0K——
Stock-based compensation $71.4M$48.4M$35.0M$27.0M$23.1M$12.6M$6.1M——
Capital expenditure $954.0K$993.0K$109.0K$278.0K$24.0K$225.0K$281.0K——
Investing cash flow -$24.0M-$90.1M-$107.2M$7.7M$48.5M$37.9M-$127.8M——
Financing cash flow $40.1M$17.7M$336.6M$109.1M$73.5M$181.3M$127.2M——

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001759425-26-000027.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -200M 0 200M 400M 600M Net income, FY2019: -52.6M Revenue, FY2020: 0 Net income, FY2020: -103.3M Revenue, FY2021: 19.1M Net income, FY2021: -84M Revenue, FY2022: 77.1M Net income, FY2022: -135.7M Revenue, FY2023: 186.4M Net income, FY2023: -163.4M Revenue, FY2024: 336.9M Net income, FY2024: -87.9M Revenue, FY2025: 521.3M Net income, FY2025: -23.4M FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — — — $0 $19.1M $77.1M $186.4M $336.9M $521.3M
Gross profit — — — — — — — — —
Net income — — -$52.6M -$103.3M -$84.0M -$135.7M -$163.4M -$87.9M -$23.4M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced Item 2.02
  • Other event Item 8.01
  • Other event Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%